The European market recently showed a mix of optimism and caution, with major stock indexes like France’s CAC 40 and Germany’s DAX posting gains amid hopes for new trade deals, although concerns about potential U.S. tariffs tempered enthusiasm. In such a climate, investors often look beyond the well-known giants to explore opportunities in smaller or newer companies that may offer growth at lower price points. Penny stocks, despite being an older term, continue to represent this potential by combining affordability with the possibility for significant returns when backed by solid financials.
Top 10 Penny Stocks In Europe
| Name | Share Price | Market Cap | Rewards & Risks |
| Lucisano Media Group (BIT:LMG) | €0.95 | €14.11M | ✅ 3 ⚠️ 4 View Analysis > |
| Maps (BIT:MAPS) | €3.42 | €45.43M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| IAMBA Arad (BVB:FERO) | RON0.498 | RON16.57M | ✅ 2 ⚠️ 4 View Analysis > |
| Cellularline (BIT:CELL) | €2.83 | €59.69M | ✅ 4 ⚠️ 2 View Analysis > |
| Fondia Oyj (HLSE:FONDIA) | €4.75 | €17.76M | ✅ 2 ⚠️ 3 View Analysis > |
| Abak (WSE:ABK) | PLN4.20 | PLN11.32M | ✅ 2 ⚠️ 4 View Analysis > |
| Bredband2 i Skandinavien (OM:BRE2) | SEK2.44 | SEK2.34B | ✅ 4 ⚠️ 1 View Analysis > |
| Deceuninck (ENXTBR:DECB) | €2.16 | €298.22M | ✅ 3 ⚠️ 1 View Analysis > |
| Netgem (ENXTPA:ALNTG) | €0.97 | €32.71M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 331 stocks from our European Penny Stocks screener.
Let's uncover some gems from our specialized screener.
BrainCool (OM:BRAIN)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: BrainCool AB (publ) is a medical device company that develops, markets, and sells medical cooling systems for the healthcare sector in Sweden, with a market cap of SEK413.03 million.
Operations: The company generates its revenue from the Medical Products segment, totaling SEK44.68 million.
Market Cap: SEK413.03M
BrainCool AB, with a market cap of SEK413.03 million, remains unprofitable despite increasing sales from SEK9.42 million to SEK11.4 million year-over-year in Q1 2025. The company has no debt and its short-term assets significantly cover both short and long-term liabilities, yet it faces financial strain with less than a year of cash runway if current cash flow trends persist. While the management team is experienced, the board lacks tenure depth. Trading at a significant discount to estimated fair value, BrainCool's earnings are forecasted to grow substantially by 106% annually amid ongoing volatility concerns.
- Click to explore a detailed breakdown of our findings in BrainCool's financial health report.
- Examine BrainCool's earnings growth report to understand how analysts expect it to perform.
SHL Telemedicine (SWX:SHLTN)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: SHL Telemedicine Ltd. offers telemedicine services across Israel, Europe, and other international markets with a market cap of CHF31.06 million.
Operations: The company's revenue is derived entirely from its telemedicine services, totaling $56.78 million.
Market Cap: CHF31.06M
SHL Telemedicine Ltd., with a market cap of CHF31.06 million, faces significant challenges as it remains unprofitable with a net loss of US$28.1 million for 2024, widening from the previous year. Despite stable weekly volatility, its share price has been highly volatile recently. The company benefits from sufficient cash runway exceeding three years and short-term assets covering liabilities, though its debt-to-equity ratio has increased to 26.5% over five years. Management's inexperience and delayed SEC filings add to investor concerns, while the board is experienced with an average tenure of 5.6 years.
- Jump into the full analysis health report here for a deeper understanding of SHL Telemedicine.
- Gain insights into SHL Telemedicine's historical outcomes by reviewing our past performance report.
4MASS Spólka Akcyjna (WSE:4MS)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: 4Mass Spólka Akcyjna is involved in the manufacture and distribution of make-up products, with a market capitalization of PLN110.45 million.
Operations: The company generates revenue of PLN116.10 million from its production and distribution of cosmetic products.
Market Cap: PLN110.45M
4MASS Spólka Akcyjna, with a market cap of PLN110.45 million, has shown stable revenue growth, reporting PLN27.87 million for Q1 2025. Although net income decreased to PLN2.3 million from the previous year, the company maintains high-quality earnings and a strong return on equity at 21%. Its debt is well-managed, with interest payments covered 29.3 times by EBIT and more cash than total debt. Despite recent negative earnings growth and a less experienced board averaging 2.1 years in tenure, its price-to-earnings ratio of 7.1x suggests it could be undervalued compared to the Polish market average.
- Click here to discover the nuances of 4MASS Spólka Akcyjna with our detailed analytical financial health report.
- Learn about 4MASS Spólka Akcyjna's historical performance here.
Turning Ideas Into Actions
- Get an in-depth perspective on all 331 European Penny Stocks by using our screener here.
- Ready To Venture Into Other Investment Styles? We've found 18 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if 4MASS Spólka Akcyjna might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com